Venous thromboembolism is a very common and costly health problem worldwide.
Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding …

The clinical relevance of high P-selectin levels in venous thrombosis is unknown. We
prospectively followed 544 patients with first unprovoked venous thromboembolism (VTE) …

BACKGROUND: P-selectin inhibition with protein therapeutics such as antibodies or soluble
ligands given intravenously can decrease thrombosis in a mouse ligation model of venous …

Inhibition of P-selectin by antibody or selectin antagonist decreases inflammation and
thrombosis. This study evaluates the dose-response relationship using a selectin receptor …

The inflammatory response is a well-established part of, and a prerequisite for, venous
thrombosis. To better understand the pathophysiology of venous thrombosis and to identify …

Abstract Introduction Soluble P selectin (sPsel), a member of the selectin family of cell
adhesion receptors, has been proposed as a key molecule in hemostasis and thrombosis …

The initial steps in the pathogenesis of atherosclerosis involve changes to the vascular
endothelium, which produces numerous substances involved in the regulation and …

P-selectin inhibition has been evaluated as a therapeutic for prevention and treatment of
venous thrombosis. In this study, a novel oral small-molecule inhibitor of P-selectin, PSI-421 …

Background. This study characterizes venous thrombosis in the mouse and examines the
important role that the adhesion molecules P-selectin and E-selectin and the anti …

BACKGROUND: P-selectin antagonism has been shown to decrease thrombogenesis and
inflammation in animal models of deep venous thrombosis (DVT). OBJECTIVE: To …